Maxpro Capital Acquisition (JMAC) Competitors $5.32 -0.08 (-1.39%) As of 05/20/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock JMAC vs. CMPX, ATYR, IMMP, TSVT, CADL, HRTX, CGC, RNAC, AVTE, and LFCRShould you be buying Maxpro Capital Acquisition stock or one of its competitors? The main competitors of Maxpro Capital Acquisition include Compass Therapeutics (CMPX), Atyr PHARMA (ATYR), Immutep (IMMP), 2seventy bio (TSVT), Candel Therapeutics (CADL), Heron Therapeutics (HRTX), Canopy Growth (CGC), Cartesian Therapeutics (RNAC), Aerovate Therapeutics (AVTE), and Lifecore Biomedical (LFCR). These companies are all part of the "pharmaceutical products" industry. Maxpro Capital Acquisition vs. Compass Therapeutics Atyr PHARMA Immutep 2seventy bio Candel Therapeutics Heron Therapeutics Canopy Growth Cartesian Therapeutics Aerovate Therapeutics Lifecore Biomedical Maxpro Capital Acquisition (NASDAQ:JMAC) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap manufacturing companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, profitability, institutional ownership, dividends, analyst recommendations, valuation and community ranking. Does the MarketBeat Community favor JMAC or CMPX? Compass Therapeutics received 48 more outperform votes than Maxpro Capital Acquisition when rated by MarketBeat users. CompanyUnderperformOutperformMaxpro Capital AcquisitionN/AN/ACompass TherapeuticsOutperform Votes4881.36% Underperform Votes1118.64% Do institutionals and insiders hold more shares of JMAC or CMPX? 73.2% of Maxpro Capital Acquisition shares are held by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are held by institutional investors. 19.3% of Maxpro Capital Acquisition shares are held by insiders. Comparatively, 29.8% of Compass Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is JMAC or CMPX more profitable? Maxpro Capital Acquisition's return on equity of 0.00% beat Compass Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Maxpro Capital AcquisitionN/A N/A N/A Compass Therapeutics N/A -32.37%-30.67% Do analysts recommend JMAC or CMPX? Compass Therapeutics has a consensus target price of $13.13, suggesting a potential upside of 537.14%. Given Compass Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Compass Therapeutics is more favorable than Maxpro Capital Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Maxpro Capital Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Compass Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 Does the media refer more to JMAC or CMPX? In the previous week, Compass Therapeutics had 2 more articles in the media than Maxpro Capital Acquisition. MarketBeat recorded 2 mentions for Compass Therapeutics and 0 mentions for Maxpro Capital Acquisition. Compass Therapeutics' average media sentiment score of 0.50 beat Maxpro Capital Acquisition's score of 0.00 indicating that Compass Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Maxpro Capital Acquisition Neutral Compass Therapeutics Neutral Which has more risk & volatility, JMAC or CMPX? Maxpro Capital Acquisition has a beta of 0.01, indicating that its share price is 99% less volatile than the S&P 500. Comparatively, Compass Therapeutics has a beta of 1.4, indicating that its share price is 40% more volatile than the S&P 500. Which has stronger valuation and earnings, JMAC or CMPX? Maxpro Capital Acquisition has higher earnings, but lower revenue than Compass Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMaxpro Capital AcquisitionN/AN/AN/AN/AN/ACompass Therapeutics$850K335.13-$42.49M-$0.41-5.02 SummaryCompass Therapeutics beats Maxpro Capital Acquisition on 10 of the 13 factors compared between the two stocks. Get Maxpro Capital Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for JMAC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart JMAC vs. The Competition Export to ExcelMetricMaxpro Capital AcquisitionHolding Offices IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$71.50M$477.17M$2.04B$8.39BDividend YieldN/A7.55%2.63%4.10%P/E RatioN/A2.5322.6819.71Price / SalesN/A70.7259.06117.54Price / CashN/A69.0151.7234.62Price / BookN/A6.842.084.50Net IncomeN/A$35.22M-$292.00M$248.18M7 Day Performance8.45%0.45%0.08%0.23%1 Month Performance-9.90%3.32%10.19%12.39%1 Year Performance1,767.77%24.62%11.36%7.07% Maxpro Capital Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)JMACMaxpro Capital AcquisitionN/A$5.33-1.4%N/A+1,580.3%$71.50MN/A0.002,021Gap UpCMPXCompass Therapeutics3.6803 of 5 stars$2.00flat$13.13+556.3%+28.8%$276.57M$850,000.00-5.4120ATYRAtyr PHARMA2.8167 of 5 stars$3.03-8.5%$18.60+513.9%N/A$269.68M$235,000.00-3.2253Analyst ForecastHigh Trading VolumeIMMPImmutep1.4044 of 5 stars$1.83-3.2%$8.50+364.5%-39.9%$267.25M$5.14M0.002,021Gap DownTSVT2seventy bio1.5487 of 5 stars$5.00flat$4.25-15.0%N/A$266.15M$37.86M-2.69440Positive NewsCADLCandel Therapeutics2.0276 of 5 stars$5.34-0.9%$21.00+293.3%-55.4%$263.10M$120,000.00-3.0960Gap UpHRTXHeron Therapeutics3.8592 of 5 stars$1.72-6.5%$5.50+219.8%-45.3%$262.41M$148.52M-9.56300Positive NewsCGCCanopy Growth1.4083 of 5 stars$1.41-2.8%$2.00+41.8%-82.2%$259.25M$276.75M-0.373,150Trending NewsRNACCartesian Therapeutics1.5386 of 5 stars$9.98-2.2%$42.50+325.9%-62.3%$258.85M$34.17M-0.1964News CoverageAnalyst RevisionAVTEAerovate Therapeutics1.6212 of 5 stars$8.61+0.3%$78.75+814.6%-98.9%$249.56MN/A-2.8820Positive NewsGap UpHigh Trading VolumeLFCRLifecore Biomedical1.2515 of 5 stars$6.67-4.0%$8.00+19.9%+8.2%$246.96M$130.31M-11.91690Analyst ForecastGap Up Related Companies and Tools Related Companies CMPX Competitors ATYR Competitors IMMP Competitors TSVT Competitors CADL Competitors HRTX Competitors CGC Competitors RNAC Competitors AVTE Competitors LFCR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:JMAC) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredExclusive Offer: Target 100% Returns NowBrace yourself–this may come as a shock. It turns out that you may not have to wait decades to turn a small...ProsperityPub | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Maxpro Capital Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Maxpro Capital Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy JMAC Stock Free JMAC Stock Alerts